Technical Analysis for GRFS - Grifols, S.A.

Grade Last Price % Change Price Change
C 17.98 -1.59% -0.29
GRFS closed down 1.59 percent on Friday, April 16, 2021, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical GRFS trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength -1.59%
Up 3 Days in a Row Strength -1.59%
Stochastic Sell Signal Bearish 0.67%
200 DMA Support Bullish 0.67%
Overbought Stochastic Strength 0.67%
Crossed Above 200 DMA Bullish 0.73%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.73%
Inside Day Range Contraction 0.73%
Older End-of-Day Signals for GRFS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 10 hours ago
60 Minute Opening Range Breakout 1 day ago
200 DMA Support 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Grifols, S.A. Description

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Infectious Diseases Clinics Healthcare Providers Antibody Hematology In Vitro Nutrition Products Hemophilia Blood Plasma End Products Transfusion Medicine European Union Analytical Instruments Blood Bank Ibex 35 In Vitro Diagnostics Diagnostics Products Factor Vii Derivative Products Factor Ix Bank Products Blood Donation Infusion Solutions Parenteral Nutrition Plasma Products

Is GRFS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.88
52 Week Low 14.81
Average Volume 901,184
200-Day Moving Average 17.82
50-Day Moving Average 16.67
20-Day Moving Average 17.27
10-Day Moving Average 17.64
Average True Range 0.59
ADX 17.64
+DI 24.71
-DI 15.11
Chandelier Exit (Long, 3 ATRs ) 16.64
Chandelier Exit (Short, 3 ATRs ) 17.67
Upper Bollinger Band 18.46
Lower Bollinger Band 16.07
Percent B (%b) 0.8
BandWidth 13.85
MACD Line 0.38
MACD Signal Line 0.29
MACD Histogram 0.0987
Fundamentals Value
Market Cap 12.31 Billion
Num Shares 685 Million
EPS 0.60
Price-to-Earnings (P/E) Ratio 29.99
Price-to-Sales 2.00
Price-to-Book 2.01
PEG Ratio 2.06
Dividend 0.42
Dividend Yield 2.34%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.51
Resistance 3 (R3) 18.51 18.34 18.42
Resistance 2 (R2) 18.34 18.21 18.34 18.39
Resistance 1 (R1) 18.16 18.12 18.25 18.16 18.36
Pivot Point 17.99 17.99 18.04 17.99 17.99
Support 1 (S1) 17.81 17.86 17.90 17.81 17.60
Support 2 (S2) 17.64 17.77 17.64 17.57
Support 3 (S3) 17.46 17.64 17.54
Support 4 (S4) 17.46